Supplementary Figure 1: Receiver operating curves for (i) PRS$_{CD}$, and (ii) PRS$_{UC}$, respectively in UK Biobank (Testing)

(i) **PRS$_{CD}$**

AUC-CD

AUC: 0.715 (0.688–0.742)

(ii) **PRS$_{UC}$**


AUC-UC

AUC: 0.663 (0.644–0.683)

Supplementary Figure 2: Receiver operating curves for (i) PRS$_{CD}$, and (ii) PRS$_{UC}$, respectively in BioVU (Validation cohort)

(i) **PRS$_{CD}$**

AUC-CD-BioVU

AUC: 0.722 (0.708–0.736)

(ii) **PRS$_{UC}$**

AUC-UC-BioVU

AUC: 0.653 (0.626–0.680)

Supplementary Figure 3: Differences in the mean PRS$_{UC}$ by immune checkpoint inhibitor-mediated colitis (All-grade and severe) in the GeRI cohort

Supplementary Figure 4: Associations of known ulcerative colitis-associated HLA markers (frequency ≥0.01) with all-grade immune checkpoint inhibitor-mediated colitis in the GeRI cohort.

Supplementary Figure 5: Immune checkpoint inhibitor-mediated colitis (IMC) as a predictor of progression-free survival (PFS) in the GeRI cohort (i) All-grade IMC, (iii) Severe IMC. Kaplan–Meier survival curves are unadjusted and compare those who had an IMC (all-grade or severe) with those who did not have an IMC (No IMC). The p-values in the graph represent the log-rank p-values and the dotted line represents median survival time. Graphs are cox proportional hazards models with 90-day landmark.

(ii) All-grade IMC (Landmark analysis)

(iv) Severe IMC (Landmark analysis)